(Q37940632)

2 April 2018

review article

1 reference

title

Potential new approaches to modifying intestinal GLP-1 secretion in patients with type 2 diabetes mellitus: focus on bile acid sequestrants (English)

1 reference

2 April 2018

0 references

Jens Juul Holst

1

0 references

author name string

Maria A McGill

series ordinal

2

1 reference

2 April 2018

publication date

1 January 2012

1 reference

2 April 2018

Clinical Drug Investigation

published in

1 reference

2 April 2018

volume

32

1 reference

2 April 2018

issue

1

1 reference

2 April 2018

page(s)

1-14

1 reference

2 April 2018

Global prevalence of diabetes: estimates for the year 2000 and projections for 2030

cites work

1 reference

https://api.crossref.org/works/10.2165%2F11595370-000000000-00000

Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595370-000000000-00000

Fasting plasma C-peptide and micro- and macrovascular complications in a large clinic-based cohort of type 1 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595370-000000000-00000

10-year follow-up of intensive glucose control in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595370-000000000-00000

U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595370-000000000-00000

Natural history of pancreatic islet B-cell function in type 2 diabetes mellitus studied over six years by homeostasis model assessment.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595370-000000000-00000

Glycaemic control, disease duration and beta-cell function in patients with Type 2 diabetes in a Swedish community. Skaraborg Hypertension and Diabetes Project

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595370-000000000-00000

Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595370-000000000-00000

Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595370-000000000-00000

The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595370-000000000-00000

Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595370-000000000-00000

Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595370-000000000-00000

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595370-000000000-00000

Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595370-000000000-00000

Glucagon-like peptide-1 7-36: a physiological incretin in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595370-000000000-00000

Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595370-000000000-00000

Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595370-000000000-00000

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595370-000000000-00000

Is the diminished incretin effect in type 2 diabetes just an epi-phenomenon of impaired beta-cell function?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595370-000000000-00000

Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595370-000000000-00000

Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595370-000000000-00000

Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595370-000000000-00000

Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595370-000000000-00000

Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595370-000000000-00000

Reduced gastric inhibitory polypeptide but normal glucagon-like peptide 1 response to oral glucose in postmenopausal women with impaired glucose tolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595370-000000000-00000

Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595370-000000000-00000

Impaired incretin response after a mixed meal is associated with insulin resistance in nondiabetic men.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595370-000000000-00000

Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595370-000000000-00000

Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595370-000000000-00000

The insulinotropic effect of endogenous gastric inhibitory polypeptide in normal subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595370-000000000-00000

Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595370-000000000-00000

Dipeptidyl-peptidase IV (CD26)--role in the inactivation of regulatory peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595370-000000000-00000

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595370-000000000-00000

Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595370-000000000-00000

The elimination rates of intact GIP as well as its primary metabolite, GIP 3-42, are similar in type 2 diabetic patients and healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595370-000000000-00000

The Physiology of Glucagon-like Peptide 1

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595370-000000000-00000

Regulation of Intestinal Proglucagon- Derived Peptide Secretion by Intestinal Regulatory Peptides*

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595370-000000000-00000

The effects of duodenal peptides on glucagon-like peptide-1 secretion from the ileum. A duodeno--ileal loop?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595370-000000000-00000

Neural regulation of glucagon-like peptide-1 secretion in pigs

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595370-000000000-00000

Muscarinic receptors control glucagon-like peptide 1 secretion by human endocrine L cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595370-000000000-00000

Molecular signaling of somatostatin receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595370-000000000-00000

The neurotransmitters glycine and GABA stimulate glucagon-like peptide-1 release from the GLUTag cell line.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595370-000000000-00000

Glucose sensing in L cells: a primary cell study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595370-000000000-00000

Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595370-000000000-00000

Glucagon-like peptide-1 (7-36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595370-000000000-00000

On the physiology of GIP and GLP-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595370-000000000-00000

Physiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595370-000000000-00000

The role of incretins in glucose homeostasis and diabetes treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595370-000000000-00000

The incretin system and its role in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595370-000000000-00000

Glucose-dependent insulinotropic polypeptide receptor null mice exhibit compensatory changes in the enteroinsular axis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595370-000000000-00000

Glucose-dependent insulinotropic polypeptide is a growth factor for beta (INS-1) cells by pleiotropic signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595370-000000000-00000

Glucose-dependent insulinotropic polypeptide (GIP) stimulation of pancreatic beta-cell survival is dependent upon phosphatidylinositol 3-kinase (PI3K)/protein kinase B (PKB) signaling, inactivation of the forkhead transcription factor Foxo1, and dow

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595370-000000000-00000

Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595370-000000000-00000

Suppression of glucose production by GLP-1 independent of islet hormones: a novel extrapancreatic effect

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595370-000000000-00000

The murine glucagon-like peptide-1 receptor is essential for control of bone resorption.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595370-000000000-00000

Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595370-000000000-00000

Glucagon-like peptide-1 (GLP-1) and glucose metabolism in human myocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595370-000000000-00000

Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595370-000000000-00000

Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595370-000000000-00000

Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595370-000000000-00000

The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595370-000000000-00000

Hepatic and peripheral insulin resistance: a common feature of type 2 (non-insulin-dependent) and type 1 (insulin-dependent) diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595370-000000000-00000

Studies of pancreatic alpha cell function in normal and diabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595370-000000000-00000

Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595370-000000000-00000

Relationship between obesity and diabetes in a US adult population: findings from the National Health and Nutrition Examination Survey, 1999-2006

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595370-000000000-00000

New therapeutic horizons: mapping the future of glycemic control with incretin-based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595370-000000000-00000

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595370-000000000-00000

Bile-induced secretion of glucagon-like peptide-1: pathophysiological implications in type 2 diabetes?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595370-000000000-00000

A role for intestinal endocrine cell-expressed g protein-coupled receptor 119 in glycemic control by enhancing glucagon-like Peptide-1 and glucose-dependent insulinotropic Peptide release

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595370-000000000-00000

A role for glucagon-like peptide-1 in the central regulation of feeding

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595370-000000000-00000

Is There a Role for ??-Glucosidase Inhibitors in the Prevention of Type 2 Diabetes Mellitus?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595370-000000000-00000

The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595370-000000000-00000

Prolonged and enhanced secretion of glucagon-like peptide 1 (7-36 amide) after oral sucrose due to alpha-glucosidase inhibition (acarbose) in Type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595370-000000000-00000

Miglitol suppresses the postprandial increase in interleukin 6 and enhances active glucagon-like peptide 1 secretion in viscerally obese subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595370-000000000-00000

alpha-Glucosidase inhibition (acarbose) fails to enhance secretion of glucagon-like peptide 1 (7-36 amide) and to delay gastric emptying in Type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595370-000000000-00000

Chronic administration of voglibose, an alpha-glucosidase inhibitor, increases active glucagon-like peptide-1 levels by increasing its secretion and decreasing dipeptidyl peptidase-4 activity in ob/ob mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595370-000000000-00000

PPARβ/δ activation induces enteroendocrine L cell GLP-1 production

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595370-000000000-00000

Activation of PPARdelta up-regulates fatty acid oxidation and energy uncoupling genes of mitochondria and reduces palmitate-induced apoptosis in pancreatic beta-cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595370-000000000-00000

Peroxisome proliferator-activated receptor (PPAR) beta/delta: a new potential therapeutic target for the treatment of metabolic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595370-000000000-00000

Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-α in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595370-000000000-00000

New aspects of an old drug: metformin as a glucagon-like peptide 1 (GLP-1) enhancer and sensitiser

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595370-000000000-00000

Dipeptidyl peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595370-000000000-00000

Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595370-000000000-00000

TGR5-mediated bile acid sensing controls glucose homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595370-000000000-00000

Serum bile acids are higher in humans with prior gastric bypass: potential contribution to improved glucose and lipid metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595370-000000000-00000

Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595370-000000000-00000

Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595370-000000000-00000

Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595370-000000000-00000

Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595370-000000000-00000

Colesevelam improves insulin resistance in a diet-induced obesity (F-DIO) rat model by increasing the release of GLP-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595370-000000000-00000

Colestimide lowers plasma glucose levels and increases plasma glucagon-like PEPTIDE-1 (7-36) levels in patients with type 2 diabetes mellitus complicated by hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595370-000000000-00000

Rationale and design of a prospective clinical trial program to evaluate the glucose-lowering effects of colesevelam HCl in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595370-000000000-00000

Bile acid sequestrants and the treatment of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595370-000000000-00000

Cholestyramine therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. A short-term, double-blind, crossover trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595370-000000000-00000

Glucose reabsorption from bile. Evidence for a biliohepatic circulation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595370-000000000-00000

GLP-1 and GIP are colocalized in a subset of endocrine cells in the small intestine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595370-000000000-00000

Secretion of the Incretin Hormones Glucagon-Like Peptide-1 and Gastric Inhibitory Polypeptide Correlates with Insulin Secretion in Normal Man Throughout the Day

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595370-000000000-00000

Ileal release of glucagon-like peptide-1 (GLP-1)

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595370-000000000-00000

10.2165/11595370-000000000-00000

21 January 2018

Identifiers

DOI

1 reference

2 April 2018

1 reference

2 April 2018